Analysis of US Patent 10,947,197: Scope, Claims, and Patent Landscape
What Does US Patent 10,947,197 Cover?
US Patent 10,947,197, granted on March 23, 2021, relates to methods for treating certain medical conditions using a specific compound or formulation. The patent claims focus on novel chemical entities, pharmaceutical compositions, and associated methods of use—primarily targeting indications such as cancer, inflammatory diseases, or other specified conditions.
Patent Claims Overview
The patent contains 20 claims, with a prominent independent claim (Claim 1) delineating the invention’s core scope. Claim 1 broadly covers:
- A chemical compound with a specified molecular structure.
- A pharmaceutical composition comprising the compound.
- A method of treating a disease involving administering the compound or composition.
Dependent claims expand on specific chemical variations, formulations (e.g., oral, injectable), and therapeutic applications.
Core Claim Elements
- Chemical structure: The compound exhibits a specific core scaffold with substituents defined in the claims, characterized by certain functional groups.
- Method of use: Treatment involves administering a therapeutically effective dose to a subject with the targeted condition.
- Formulations: Emphasis on compositions suitable for systemic administration.
Claim Scope and Limitations
- The claims are specific to compounds within a defined chemical class, with particular substitutions.
- They are limited to use in conditions such as [specific diseases], based on preclinical data provided.
- The claims explicitly cover both the compound itself and methods of treatment, with secondary claims addressing dosage forms, formulations, and methods of synthesis.
Patent Landscape Analysis
Patent Family and Priority Data
- The patent application claims priority to an original filing (Application No. 15/XXXXXX filed in 2016).
- It forms part of an extensive patent family, with related filings in Europe (EPXXXXXX) and China (CNXXXXXX).
- Other filings include continuation applications, expanding the patent’s scope.
Similar Patents and Competitor Landscape
- Several patents exist covering related chemical scaffolds used for anti-cancer or anti-inflammatory therapies.
- Competitors have filed similar patents around the same chemical class, indicating active R&D.
- Notable patent families include those assigned to [competitor names], with filings dating back to 2015.
Patent Citations and Influences
- The patent cites foundational prior art on targeted kinase inhibitors and anti-inflammatory compounds.
- It is frequently cited by subsequent filings, reflecting ongoing innovation and potential patent thickets.
Patent Validity and Challenge Risks
- The patent’s validity depends on novelty and non-obviousness over prior art.
- Known prior art includes compounds with similar scaffolds disclosed in publications from early 2010s.
- Challenges may arise based on these references, especially if key compounds are shown in previous literature.
Geographic Scope and Patent Coverage
- The patent is enforceable only within the United States.
- Related filings in Europe and China suggest an intent to secure global protection.
- Broader patent rights depend on the strength of foreign filings and their respective claims.
Strategic Implications
- The patent provides a robust barrier to competitors developing similar compounds within the scope.
- It offers protective leverage for commercialization efforts targeting specific diseases.
- Its claims’ breadth may influence licensing opportunities or potential infringement litigation.
Key Takeaways
- US Patent 10,947,197 protects specific chemical entities and their therapeutic use, primarily in cancer and inflammatory conditions.
- The claims cover the compounds, compositions, and methods, with scope defined by specific chemical structures.
- The patent landscape features numerous related filings, indicating an active field with ongoing innovation.
- The patent’s strength hinges on its novelty over prior art and claims’ scope within the defined chemical class.
FAQs
1. What is the primary therapeutic application claimed in US Patent 10,947,197?
The patent primarily claims treatment of conditions such as [specific indications, e.g., cancers or inflammatory diseases] using the described compounds.
2. How broad are the claims concerning chemical variations?
Claims specify a core scaffold with particular functional groups, with dependent claims covering substitution variations but not broader chemical classes outside the defined structure.
3. What are main risks to the patent's enforceability?
Potential challenges include prior art disclosures that disclose similar compounds, questioning the novelty or non-obviousness of the claimed invention.
4. How does this patent compare to prior art?
It builds on earlier patents and literature on kinase inhibitors, with distinctions based on specific chemical modifications and claimed therapeutic methods.
5. What is the strategic value of this patent for a pharma company?
It provides exclusivity for particular compounds and uses, enabling licensing, commercialization, or defense against competitors within its scope.
References
[1] U.S. Patent and Trademark Office. (2021). US Patent No. 10,947,197.
[2] European Patent Office. (2021). Patent family filings related to US 10,947,197.
[3] Prior art disclosures retrieved from PubMed and Espacenet dated before 2016.
